Skip to main content
SpringerLink
Log in

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Objective

This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC).

Methods

The study included 62 Japanese patients who were treated for CRPC with ≥ 2 courses of cabazitaxel between 2014 and 2017. The oncological outcomes and adverse events were compared between 16 (25.8%) and 46 (74.2%) men who were treated with standard 3-weekly and alternative 4-weekly regimens, respectively.

Results

The prostate-specific antigen (PSA) response was comparable between the 3-weekly and 4-weekly regimens (median [interquartile range]: − 9.9% [− 64.5 to 13.0%] and − 30.7% [− 52.8 to 10.9%], P = 0.89), respectively. For patients on the 4-weekly regimen, the risks of progression (hazard ratio [HR], 95% confidence interval [CI] 1.27, 0.71–2.43, P = 0.44), treatment failure (HR, 95% CI 0.84, 0.48–1.55, P = 0.57) and any-cause mortality (HR, 95% CI 1.09, 0.58–2.17, P = 0.79) were comparable to those for patients on the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens.

Conclusions

3-weekly and 4-weekly regimens of cabazitaxel showed similar efficacy and safety profiles in a real-world clinical setting. These data suggest that a 4-weekly regimen may be acceptable for selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shiota M, Yokomizo A, Eto M (2016) Taxane chemotherapy for Hormone-Naïve prostate cancer with its expanding role as breakthrough strategy. Front Oncol 5:304

    Article  PubMed  PubMed Central  Google Scholar 

  2. Shiota M, Eto M (2016) Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol 23:360–369

    Article  PubMed  Google Scholar 

  3. Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW (2018) Current treatment strategies for advanced prostate cancer. Int J Urol 25:220–231

    Article  PubMed  Google Scholar 

  4. Fujimoto N (2016) Novel agents for castration-resistant prostate cancer: early experience and beyond. Int J Urol 23:114–121

    Article  PubMed  Google Scholar 

  5. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators TROPIC (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  CAS  PubMed  Google Scholar 

  6. Bahl A, Oudard S, Tombal B, Ozgüroglu M, Hansen S, Kocak I, Gravis G, Devin J, Shen L, de Bono JS, Sartor AO, Investigators TROPIC (2013) Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24:2402–2408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O (2017) Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA. J Clin Oncol 35:3189–3197

    Article  CAS  PubMed  Google Scholar 

  8. Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, Kacso G, Chadjaa M, Zhang W, Bernard J, de Bono J (2017) Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 35:3198–3206

    Article  CAS  PubMed  Google Scholar 

  9. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159

    Article  PubMed  Google Scholar 

  10. Climent MÁ, Pérez-Valderrama B, Mellado B, Fernández Parra EM, Fernández Calvo O, Ochoa de Olza M, Muinelo Romay L, Anido U, Domenech M, Hernando Polo S, Arranz Arija JÁ, Caballero C, Juan Fita MJ, Castellano D (2017) Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: phase II Spanish Oncology Genitourinary Group (SOGUG) trial. Eur J Cancer 87:30–37

    Article  CAS  PubMed  Google Scholar 

  11. Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullén A (2018) Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: a randomised phase II trial (ConCab). Eur J Cancer 97:33–40

    Article  CAS  PubMed  Google Scholar 

  12. Clément-Zhao A, Auvray M, Aboudagga H, Blanc-Durand F, Angelergues A, Vano YA, Mercier F, El Awadly N, Verret B, Thibault C, Oudard S (2018) Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer. BJU Int 121:203–208

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge the contributions of the following collaborators: Akito Yamaguchi (Harasanshin Hospital, Fukuoka), Takashi Dejima (Kyushu Central Hospital, Fukuoka), Satoshi Otsubo (Kitakyushu Municipal Medical Center, Kitakyushu), Akio Tsutsui (JCHO Kyushu Hospital, Kitakyushu), and Yoshifumi Hori (Miyazaki Prefectural Miyazaki Hospital, Miyazaki). We thank Anne M. O’Rourke, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Funding

This work was supported by JSPS KAKENHI Grant (17K11145).

Author information

Authors and Affiliations

  1. Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    Masaki Shiota & Masatoshi Eto

  2. Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

    Motonobu Nakamura

  3. Division of Urology, Harasanshin Hospital, Fukuoka, Japan

    Akira Yokomizo

  4. Department of Urology, Oita Prefectural Hospital, Oita, Japan

    Toshihisa Tomoda

  5. Department of Urology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

    Naotaka Sakamoto

  6. Department of Urology, Kyushu Central Hospital, Fukuoka, Japan

    Narihito Seki

  7. Department of Urology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan

    Shuji Hasegawa

  8. Department of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan

    Takakazu Yunoki

  9. Department of Urology, JCHO Kyushu Hospital, Kitakyushu, Japan

    Masahiko Harano

  10. Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan

    Kentaro Kuroiwa

Authors
  1. Masaki Shiota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Motonobu Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Yokomizo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshihisa Tomoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naotaka Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Narihito Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shuji Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takakazu Yunoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masahiko Harano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kentaro Kuroiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masatoshi Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Shiota.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

Ethical approval

IRB approval from Kyushu University Hospital, National Hospital Organization Kyushu Cancer Center, Harasanshin Hospital, Oita Prefectural Hospital, National Hospital Organization Kyushu Medical Center, Kyushu Central Hospital, Kitakyushu Municipal Medical Center, Japanese Red Cross Fukuoka Hospital, JCHO Kyushu Hospital, and Miyazaki Prefectural Miyazaki Hospital.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shiota, M., Nakamura, M., Yokomizo, A. et al. Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study. Cancer Chemother Pharmacol 84, 561–566 (2019). https://doi.org/10.1007/s00280-019-03874-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-019-03874-7

Keywords

Search

Navigation